Gordon Catherine M, Williams Avery LeBoff, Feldman Henry A, May Jessica, Sinclair Linda, Vasquez Alex, Cox Joanne E
Divisions of Adolescent Medicine and Endocrinology, Children's Hospital Boston, 300 Longwood Avenue, Boston, MA 02115, USA.
J Clin Endocrinol Metab. 2008 Jul;93(7):2716-21. doi: 10.1210/jc.2007-2790. Epub 2008 Apr 15.
Hypovitaminosis D appears to be on the rise in young children, with implications for skeletal and overall health.
The objective of the study was to compare the safety and efficacy of vitamin D2 daily, vitamin D2 weekly, and vitamin D3 daily, combined with supplemental calcium, in raising serum 25-hydroxyvitamin D [25(OH)D] and lowering PTH concentrations.
This was a 6-wk randomized controlled trial.
The study was conducted at an urban pediatric clinic in Boston.
Forty otherwise healthy infants and toddlers with hypovitaminosis D [25(OH)D < 20 ng/ml] participated in the study.
Participants were assigned to one of three regimens: 2,000 IU oral vitamin D2 daily, 50,000 IU vitamin D2 weekly, or 2,000 IU vitamin D3 daily. Each was also prescribed elemental calcium (50 mg/kg.d). Infants received treatment for 6 wk.
Before and after treatment, serum measurements of 25(OH)D, PTH, calcium, and alkaline phosphatase were taken.
All treatments approximately tripled the 25(OH)D concentration. Preplanned comparisons were nonsignificant: daily vitamin D2 vs. weekly vitamin D2 (12% difference in effect, P = 0.66) and daily D2 vs. daily D3 (7%, P = 0.82). The mean serum calcium change was small and similar in the three groups. There was no significant difference in PTH suppression.
Short-term vitamin D2 2,000 IU daily, vitamin D2 50,000 IU weekly, or vitamin D3 2,000 IU daily yield equivalent outcomes in the treatment of hypovitaminosis D among young children. Therefore, pediatric providers can individualize the treatment regimen for a given patient to ensure compliance, given that no difference in efficacy or safety was noted among these three common treatment regimens.
维生素D缺乏症在幼儿中似乎呈上升趋势,这对骨骼和整体健康都有影响。
本研究的目的是比较每日补充维生素D2、每周补充维生素D2以及每日补充维生素D3并联合补充钙,在提高血清25-羟基维生素D[25(OH)D]水平和降低甲状旁腺激素(PTH)浓度方面的安全性和有效性。
这是一项为期6周的随机对照试验。
该研究在波士顿的一家城市儿科诊所进行。
40名患有维生素D缺乏症[25(OH)D<20 ng/ml]的健康婴幼儿参与了本研究。
参与者被分配到三种治疗方案之一:每日口服2000 IU维生素D2、每周口服50000 IU维生素D2或每日口服2000 IU维生素D3。每种方案还同时开具了元素钙(50 mg/kg·d)。婴儿接受治疗6周。
在治疗前后,检测血清中的25(OH)D、PTH、钙和碱性磷酸酶水平。
所有治疗方案均使25(OH)D浓度增加了约两倍。预先计划的比较无显著差异:每日维生素D2与每周维生素D2(效果差异12%,P = 0.66)以及每日维生素D2与每日维生素D3(差异7%,P = 0.82)。三组的血清钙平均变化较小且相似。PTH抑制方面无显著差异。
对于幼儿维生素D缺乏症的治疗,每日补充2000 IU维生素D2、每周补充50000 IU维生素D2或每日补充2000 IU维生素D3产生的效果相当。因此,鉴于这三种常见治疗方案在疗效和安全性上没有差异,儿科医疗服务提供者可以为特定患者制定个性化的治疗方案以确保依从性。